The results? Stunning. At the intervention site, traditional treatments for severe ROP plummeted from 72% to 13%. Meanwhile, control sites saw a rise in treatment needs. Talk about a major win for the dexamethasone team! They even noted that most severe ROP regressions happened within just four weeks of using these drops. That’s impressive.
Yet, despite these promising numbers, dexamethasone eye drops aren’t the standard treatment yet. Why? Well, there’s a lot of hesitance about using it off-label. Sure, it’s showing potential to prevent progression to Type 1 ROP, but it’s still not a go-to. The medical community loves its cautious approach—can’t blame them, but it can be frustrating.
Despite its potential, dexamethasone eye drops remain off-label, as the medical community prioritizes caution over quick adoption.
Safety is a concern, too. Adverse events like high intraocular pressure and growth restriction have been reported. They’re keeping a close eye on these infants, tracking their growth and vision for years. That’s good, but it still leaves a lot of questions hanging in the air. Additionally, the rising survival rates of preterm infants contribute to the urgency for effective ROP treatments. Furthermore, the use of dexamethasone has led to a significant decline in the need for traditional treatments at the intervention site.
And let’s be real: the data on safety and efficacy in neonates is still shaky at best. The study’s authors are clear about needing more trials before this becomes a standard.
